Patent ID: 8623919

Claim:
A method of treating myocardial infarction by elevating endogenous H2S level in infarcted myocardial cells thereby improving survival rate of the myocardial cells comprising administrating to a subject in injection form with an effective amount of pharmaceutical composition comprising S-propargyl-cysteine (SPRC) that is capable of inducing a measurable cystathionine-γ-lyase (CSE) activity in the myocardial cells, wherein said SPRC is artificially synthesized from cysteine hydrochloride in an aqueous solution, wherein the effective amount of SPRC is at least 50 mg/Kg/day, wherein the subject is suffering from myocardial cell infarction and wherein said SPRC is administered for at least 2 days after the occurrence of the infarction.